←Back to Expert Scholars
Translational Medicine / 转化医学ADC Lineage Targets
Ian Krop
MD, PhD
🏢Yale Cancer Center🌐USA
Chief Clinical Research Officer
80
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Ian Krop has led pivotal trials of HER2 directed ADCs including trastuzumab emtansine and trastuzumab deruxtecan in breast cancer. His research focuses on mechanisms of ADC resistance and strategies to extend benefit across HER2 expression levels. He has shaped the clinical integration of lineage targeting ADCs.
Share:
🧪Research Fields 研究领域
antibody drug conjugates
HER2
breast cancer
ADC resistance
trastuzumab emtansine
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Ian Krop 的研究动态
Follow Ian Krop's research updates
留下邮箱，当我们发布与 Ian Krop（Yale Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment